A Phase IIa, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Efficacy of DA-9805 in Subjects With Parkinson's Disease
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Jan 2019
At a glance
- Drugs DA 9805 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions; First in man
- Sponsors Dong-A ST
- 01 Jan 2019 Planned primary completion date changed from 1 Jan 2019 to 1 Mar 2019.
- 01 Jan 2019 Status changed from recruiting to active, no longer recruiting.
- 23 Feb 2018 Status changed from not yet recruiting to recruiting.